Paroxetine shifts imipramine metabolism

Psychiatry Research

Volumn 59, Issue 3, 1996, Pages 189-196

  Albers, Lawrence J ^a,b   Reist, Christopher ^a,b   Helmeste, Daiga ^a,b   Vu, Ryan ^a   Tang, Siu Wa ^a,b  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antidepressant; Desipramine; Human cytochrome P450; Pharmacokinetics; Serotonin reuptake inhibitor; Tricyclic

Indexed keywords

DESIPRAMINE; IMIPRAMINE; PAROXETINE;

ADULT; ARTICLE; CLINICAL ARTICLE; DEPRESSION; DRUG COMBINATION; DRUG METABOLISM; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; PRIORITY JOURNAL; SEDATION; SIDE EFFECT; XEROSTOMIA;

EID: 0030022593     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/0165-1781(95)02822-6     Document Type: Article

References (25)

1. Alderman, J.A., Allison, J., Chung, M., Harrison, W. and Greenblatt, D.J. (1994) Desipramine with paroxetine or sertraline. Presented at the Annual Meeting of the American Psychiatric Association, Philadelphia, PA, May 21-26.
2. Alvan, G., Bechtel, P., Iselius, L. and Gundert-Remy, U. (1990) Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 39, 533-537.
3. Aranow, R.B., Hudson, J.I., Pope, G., Grady, T.A., Laage, T.A., Bell, I.R. and Cole, J.O. (1989) Elevated antidepressant plasma levels after addition of fluoxetine. Am J Psychiatry 146, 911-913.
4. Baron, B.M., Ogden, A., Siegel, B.W., Stegeman, J., Ursillo, R.C. and Dudley, M.W. (1988) Rapid down-regulation of β-adrenoceptors by co-administration of desipramine and fluoxetine. Eur J Pharmacol 154, 125-134.
5. Barros, J. and Asnis, G. (1993) An interaction of sertraline and desipramine. (Letter) Am J Psychiatry 150, 1751.
6. Bergstrom, R.F., Peyton, A.L. and Lemberger, L. (1992) Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther 51, 239-248.
7. Brett, M.A., Dierdorf, H., Zussman, B.D. and Coates, P.E. (1987) Determination of paroxetine in human plasma using high performance liquid chromatography with fluorescence detection. J Chromatogr 419, 438-444.
8. Brosen, K., Hansen, J.G., Nielson, K.K., Sindrup, S.H. and Gram, L.F. (1993) Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol 44, 349-355.
9. Brosen, K., Zeugin, T. and Meyer, U.A. (1991) Role of P450IID6, the target of the sparteine-debrisoquine oxidation polymorphism in the metabolism of imipramine. Clin Pharmacol Ther 49, 609-617.
10. Crewe, H.K., Lennard, M.S., Tucker, G.T., Woods, F.R. and Haddock, R.E. (1992) The effect of selective serotonin reuptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 34, 262-265.
11. DeVane, (1992) Pharmacokinetics of the selective serotonin reuptake inhibitors. J Clin Psychiatry 53 (Suppl. 2), 13-20.
12. Kaye, C.M., Haddock, R.E., Langley, P.F., Mellows, G., Tasker, T.C.G., Zussman, B.D. and Greb, W.H. (1989) A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand 80 (Suppl. 350), 60-75.
13. Lemoine, A., Gautier, J.C., Azoulay, D., Kiffel, L., Belloc, C., Guengerich, F.P., Maurel, P., Beaune, P. and Leroux, J.P. (1993) Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. Mol Pharmacol 43, 827-832.
14. Lydiard, R.B., Anton, R.F. and Cunningham, T. (1993) Interactions between sertraline and tricyclic antidepressants. (Letter) Am J Psychiatry 150, 1125-1126.
15. Nelson, J.C., Mazure, C.M., Bowers, B. and Jatlow, P.I. (1991) A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 48, 303-307.
16. Otton, S.V., Ball, S.E., Cheung, S.W., Inaba, T. and Sellers, E.M. (1994) Comparative inhibition of the polymorphic enzyme CYP2D6 by venlafaxine (VF) and other 5HT uptake inhibitors. Clin Pharmacol Ther 55(2), 141.
17. Preskorn, S.H., Alderman, J., Chung, M., Harrison, W., Messig, M. and Harris, S. (1994) Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 14, 90-98.
18. Reece, P.A., Zacrest, R. and Barrow, C.G. (1979) Quantification of imipramine and desipramine in plasma by high-performance liquid chromatography and fluorescence detection. J Chromatogr 163, 310-314.
19. Schildkraut, J.J. (1974) Biogenic amines and affective disorders. Annu Rev Med 25, 333-348.
20. Sesardic, D., Boobis, A.R., Edwards, R.J. and Davies, D.S. (1988) A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. J Clin Pharmacol 26, 363-372.
21. Skjelbo, E. and Brosen, K. (1992) Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol 34, 256-261.
22. Skjelbo, E., Brosen, K., Hallas, J. and Gram, L.F. (1991) The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clin Pharmacol Ther 49, 18-23.
23. Spina, E., Pollicino, A.M., Avenso, A., Campo, G.M., Perucca, E. and Caputi, A.P. (1993) Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Ther Drug Monit 15(3), 243-246.
24. Vaughan, D.A. (1988) Interaction of fluoxetine with tricyclic antidepressants. (Letter) Am J Psychiatry 145(11), 1478.
25. Weilburg, J.B., Rosenbaum, J.F., Biederman, J., Sachs, G.S., Pollack, M.H. and Kelly, K. (1989) Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: a preliminary report. J Clin Psychiatry 50, 447-449.